Baillie Gifford & Co
SMMT icon

Baillie Gifford & Co’s Summit Therapeutics SMMT Stock Holding History

Baillie Gifford & Co’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-436,512
Closed -$1.07M – 507
2022
Q1 		$1.07M Hold
436,512
– – ﹤0.01% 274
2021
Q4 		$1.17M Hold
436,512
– – ﹤0.01% 275
2021
Q3 		$2.19M Hold
436,512
– – ﹤0.01% 264
2021
Q2 		$3.26M Buy
436,512
+64,251
+17% +$421K ﹤0.01% 263
2021
Q1 		$2.19M Hold
372,261
– – ﹤0.01% 256
2020
Q4 		$1.75M Hold
372,261
– – ﹤0.01% 245
2020
Q3 		$1.28M Buy
+372,261
New +$1.29M ﹤0.01% 237

Other funds holding SMMT

PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AGM
Alpine Global Management New York $615M AUM 34.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Baillie Gifford & Co's SMMT Position: Q2 2022 in Review

Baillie Gifford & Co sold out of Summit Therapeutics (SMMT) in Q2 2022, closing a stake of 436,512 shares — an estimated $1.07M sold.

Baillie Gifford & Co first reported a position in SMMT in Q3 2020 and held it in 7 quarters. The position peaked at $3.26M in Q2 2021. 45 funds tracked by Wall St. Rank hold SMMT as of Q2 2022.

  • Baillie Gifford & Co reported no remaining Summit Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Baillie Gifford & Co sold 436,512 Summit Therapeutics shares in Q2 2022, an estimated $1.07M.
  • Baillie Gifford & Co first reported a position in Summit Therapeutics in Q3 2020 and held it in 7 quarters.
  • Baillie Gifford & Co's Summit Therapeutics position peaked at $3.26M in Q2 2021.
  • 45 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2022.

Based on Baillie Gifford & Co's 13F filing for Q2 2022, filed 8 Aug 2022.